Abstract
Human laboratory studies have a rich history in the alcoholism field and several important determinants of alcohol use disorders have been successfully modeled under controlled laboratory conditions. Laboratory paradigms have been employed to identify biobehavioral risk markers for alcohol misuse and more recently, have been integrated with behavioral genetic, neuroimaging, and pharmacological approaches to further elucidate the neuropathophysiology of addiction and to screen for efficacious treatments. This review will address the rationale and application of human laboratory models to advance pharmacotherapy development for alcohol dependence. It is argued that when properly implemented, laboratory models may help scientists and clinicians understand mechanisms of pharmacotherapy response, which in turn may inform efforts to optimize the currently available and newly developed treatments for alcoholism. Limitations and future directions are discussed.
Keywords: Alcohol, laboratory studies, craving, pharmacotherapy, genetics
Current Pharmaceutical Design
Title: Application of Human Laboratory Models to Pharmacotherapy Development for Alcohol Dependence
Volume: 16 Issue: 19
Author(s): Lara A. Ray, Kent E. Hutchison and Molly Tartter
Affiliation:
Keywords: Alcohol, laboratory studies, craving, pharmacotherapy, genetics
Abstract: Human laboratory studies have a rich history in the alcoholism field and several important determinants of alcohol use disorders have been successfully modeled under controlled laboratory conditions. Laboratory paradigms have been employed to identify biobehavioral risk markers for alcohol misuse and more recently, have been integrated with behavioral genetic, neuroimaging, and pharmacological approaches to further elucidate the neuropathophysiology of addiction and to screen for efficacious treatments. This review will address the rationale and application of human laboratory models to advance pharmacotherapy development for alcohol dependence. It is argued that when properly implemented, laboratory models may help scientists and clinicians understand mechanisms of pharmacotherapy response, which in turn may inform efforts to optimize the currently available and newly developed treatments for alcoholism. Limitations and future directions are discussed.
Export Options
About this article
Cite this article as:
A. Ray Lara, E. Hutchison Kent and Tartter Molly, Application of Human Laboratory Models to Pharmacotherapy Development for Alcohol Dependence, Current Pharmaceutical Design 2010; 16 (19) . https://dx.doi.org/10.2174/138161210791516422
DOI https://dx.doi.org/10.2174/138161210791516422 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Emerging Therapies in Relapsing-Remitting Multiple Sclerosis
Reviews on Recent Clinical Trials Beneficial Extracardiac Effects of Cardiovascular Medications
Current Cardiology Reviews Renin-Angiotensin-Aldosterone System: A Current Drug Target for the Management of Neuropathic Pain
Current Drug Targets Prevention of Macrovascular Disease in Type 2 Diabetic Patients: Blockade of the Renin-Angiotensin-Aldosterone System
Current Diabetes Reviews Medication Assisted Treatment in the Treatment of Drug Abuse and Dependence in HIV/AIDS Infected Drug Users
Current HIV Research IgE-Mediated Disorders: Current Therapeutics and New Strategies Involving Synthetic Peptides
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies
Current Clinical Pharmacology Systematic Review and Meta-analysis of Flibanserin's Effects and Adverse Events in Women with Hypoactive Sexual Desire Disorder
Current Drug Metabolism The Use of Nitric Oxide Synthase Inhibitors in Inflammatory Diseases: A Novel Class of Anti-Inflammatory Agents
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Direct Covalent Modification as a Strategy to Inhibit Nuclear Factor-Kappa B
Current Medicinal Chemistry Anacetrapib: A New Weapon Against Dyslipidemia
Current Clinical Pharmacology Exercise for Fibromyalgia Pain: A Meta-Analysis of Randomized Controlled Trials
Current Rheumatology Reviews Targeting Dopaminergic System for Treating Nicotine Dependence
Central Nervous System Agents in Medicinal Chemistry Integrating Pathophysiology in Migraine: Role of the Gut Microbiome and Melatonin
Current Pharmaceutical Design Nitric Oxide in Migraine
CNS & Neurological Disorders - Drug Targets Novel Coronavirus SARS-CoV-2 (COVID-19) and Pregnancy: A Hypothetical View
Endocrine, Metabolic & Immune Disorders - Drug Targets Thromboembolic Complications in Malignant Haematological Disorders
Current Vascular Pharmacology Secondary Hypertension: The Ways of Management
Current Vascular Pharmacology Existing and Emerging Therapies for Acute Gout and Long-Term Urate Lowering
Current Rheumatology Reviews Emerging Use of Nanotechnology in the Treatment of Neurological Disorders
Current Pharmaceutical Design